Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group.

Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group. | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group. Xiaodong Mo, Qi Wen, Chuanhe Jiang, Xiaodan Liu, Yi Xia, Yilei Ma, and 9 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5222638/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract It was commonly accepted that adverse-risk acute myeloid leukemia patients should receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1). In this multicenter study, we aimed to compare the post-transplant outcomes between patients receiving venetoclax with azacitidine (VEN-AZA, n = 47) and intensive chemotherapy (IC, n = 264) before allo-HSCT. In total cohort, the 3-year probabilities of overall survival, leukemia-free survival, and event-free survival of IC group were all better than VEN-AZA group, particularly for the patients with ASXL1 mutation or with SF3B1 mutation. Even in the patients ≥ 55 years or those with HCT-CI ≥ 1 scores before allo-HSCT, the survival of VEN-AZA group was not superior to the IC group. After propensity score matching, the overall survival at 1 year after allo-HSCT for IC group was better than that of VEN-AZA group (93.6 vs. 78.0%, P = 0.034), and the other clinical outcomes were comparable between VEN-AZA and IC groups. TP53 mutation was the most important adverse prognostic factor for post-transplant relapse and survival. Thus, our results did not support the preferential use of VEN-AZA over IC regimens in young and medical fit adverse-risk AML patients who would receive allo-HSCT in CR1. Biological sciences/Cancer/Haematological cancer/Leukaemia/Acute myeloid leukaemia Health sciences/Diseases/Haematological diseases/Haematological cancer/Leukaemia/Acute myeloid leukaemia Health sciences/Diseases/Cancer/Haematological cancer/Leukaemia/Acute myeloid leukaemia Health sciences/Diseases/Cancer/Cancer therapy/Chemotherapy Biological sciences/Immunology/Bone marrow transplantation Figures Figure 1 Figure 2 Figure 3 Figure 4 Full Text Additional Declarations There is NO conflict of interest to disclose. Supplementary Files SupplementalAppendix.docx Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5222638","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":367297897,"identity":"79711c81-41bf-4fd5-bf7a-f9a780815f7a","order_by":0,"name":"Xiaodong Mo","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7ElEQVRIiWNgGAWjYJCCAwwMzECK+RiDBJifQLQWtjTitTBAtPCYQTkEtOi29xge+FFhLWfOv+bbA8ucwwz87DkGDD934NZiduZYwsGeM+nGljPebjeQ3HaYQbLnjQFj7xk8Wm4kHzjA23Y4ccONs9skQFoMbuQYMDO24dOS2HDwL1jLmWdgLfaEtSQfOAy25XwPG8QWCUJagH45LAP0i8ENNnOgX9J5JM48KzjYi0/L8R7jj2+AIWZw/vCzx5LbrOX425M3PviJRwsCSCQwMAOjkgfEPkCMBgYG/gMMjB+IUzoKRsEoGAUjDAAAE4VYWb8VX6YAAAAASUVORK5CYII=","orcid":"","institution":"Peking University People's Hospital, Peking University Institute of Hematology","correspondingAuthor":true,"prefix":"","firstName":"Xiaodong","middleName":"","lastName":"Mo","suffix":""},{"id":367297898,"identity":"0432a37e-0753-42e2-83ff-a360a7917b46","order_by":1,"name":"Qi Wen","email":"","orcid":"","institution":"Peking University People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Qi","middleName":"","lastName":"Wen","suffix":""},{"id":367297899,"identity":"c9855aa1-9f51-4fd9-91a3-4382d9cb55a0","order_by":2,"name":"Chuanhe Jiang","email":"","orcid":"","institution":"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Chuanhe","middleName":"","lastName":"Jiang","suffix":""},{"id":367297900,"identity":"58deccb1-6064-47c3-8602-6bf4933671d4","order_by":3,"name":"Xiaodan Liu","email":"","orcid":"","institution":"The Affiliated Hospital of Qingdao University","correspondingAuthor":false,"prefix":"","firstName":"Xiaodan","middleName":"","lastName":"Liu","suffix":""},{"id":367297901,"identity":"a03400f8-e1ce-4dc6-ba8c-b7a40f679c4c","order_by":4,"name":"Yi Xia","email":"","orcid":"","institution":"Peking University People's Hospital, Peking University Institute of Hematology","correspondingAuthor":false,"prefix":"","firstName":"Yi","middleName":"","lastName":"Xia","suffix":""},{"id":367297902,"identity":"94dd09d6-a233-4b97-85ae-b539359af470","order_by":5,"name":"Yilei Ma","email":"","orcid":"","institution":"Peking University People's Hospital, Peking University Institute of Hematology","correspondingAuthor":false,"prefix":"","firstName":"Yilei","middleName":"","lastName":"Ma","suffix":""},{"id":367297903,"identity":"86a10062-aa28-48c4-981b-1e0097b07eb5","order_by":6,"name":"Yang Yang","email":"","orcid":"","institution":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","correspondingAuthor":false,"prefix":"","firstName":"Yang","middleName":"","lastName":"Yang","suffix":""},{"id":367297904,"identity":"066eae2d-248a-4122-8bf2-22132c46c695","order_by":7,"name":"Yu Wang","email":"","orcid":"https://orcid.org/0000-0003-1253-7465","institution":"Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Tr","correspondingAuthor":false,"prefix":"","firstName":"Yu","middleName":"","lastName":"Wang","suffix":""},{"id":367297905,"identity":"e71a4d3e-5791-45c9-bc7d-e689bb4ab9c5","order_by":8,"name":"Yingjun Chang","email":"","orcid":"","institution":"Peking University People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yingjun","middleName":"","lastName":"Chang","suffix":""},{"id":367297906,"identity":"64dc0608-8aff-4d55-8a80-b10f2a5090a4","order_by":9,"name":"Luxiang Wang","email":"","orcid":"","institution":"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Luxiang","middleName":"","lastName":"Wang","suffix":""},{"id":367297907,"identity":"6d8f8818-43f2-4feb-bf83-dca1abdbb36a","order_by":10,"name":"Zilu Zhang","email":"","orcid":"","institution":"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Zilu","middleName":"","lastName":"Zhang","suffix":""},{"id":367297908,"identity":"34bbed4b-d8f8-4b10-88cc-77f8b069f5ee","order_by":11,"name":"Xiaojun Huang","email":"","orcid":"","institution":"Peking University People's Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xiaojun","middleName":"","lastName":"Huang","suffix":""},{"id":367297909,"identity":"e12c1f41-1343-4cb0-9b5c-15b619b79f91","order_by":12,"name":"Yang Cao","email":"","orcid":"","institution":"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","correspondingAuthor":false,"prefix":"","firstName":"Yang","middleName":"","lastName":"Cao","suffix":""},{"id":367297910,"identity":"0be0c666-11e8-4017-8ad1-f8204d0154ab","order_by":13,"name":"Yanmin Zhao","email":"","orcid":"https://orcid.org/0000-0003-3857-5574","institution":"The First Affiliated Hospital, Zhejiang University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Yanmin","middleName":"","lastName":"Zhao","suffix":""},{"id":367297911,"identity":"596da802-acd9-42ab-a8ee-5c5d6edec70f","order_by":14,"name":"Xiaoxia Hu","email":"","orcid":"","institution":"Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine","correspondingAuthor":false,"prefix":"","firstName":"Xiaoxia","middleName":"","lastName":"Hu","suffix":""}],"badges":[],"createdAt":"2024-10-08 06:55:34","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5222638/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5222638/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":67295056,"identity":"c7b613b1-2c10-4d37-9f20-329f59a1da03","added_by":"auto","created_at":"2024-10-23 10:52:31","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":378218,"visible":true,"origin":"","legend":"\u003cp\u003eFlow diagram of patients enrolled.\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5222638/v1/ff635028ee9744882f05ea1d.jpg"},{"id":67295057,"identity":"b8d4d293-c8f2-40be-83cc-59bcc7b3d50d","added_by":"auto","created_at":"2024-10-23 10:52:32","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":233858,"visible":true,"origin":"","legend":"\u003cp\u003eGenetic abnormalities at diagnosis.\u003c/p\u003e","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5222638/v1/2cb167b64d6b13196b34ed4d.jpg"},{"id":67294342,"identity":"f55e8de2-9103-49d0-a1c6-87d1e840e6de","added_by":"auto","created_at":"2024-10-23 10:44:27","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":514369,"visible":true,"origin":"","legend":"\u003cp\u003e3-year clinical outcomes after allo-HSCT in total cohort. (A) Relapse, (B)\u003c/p\u003e\n\u003cp\u003eNRM, (C) OS, (D) LFS, and (E) EFS.\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5222638/v1/8e59476a6472b892068b7244.jpg"},{"id":67294339,"identity":"9a6af35f-0499-445e-8ba2-c140f544773d","added_by":"auto","created_at":"2024-10-23 10:44:27","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":498857,"visible":true,"origin":"","legend":"\u003cp\u003e3-year clinical outcomes after allo-HSCT in PSM cohort. (A) Relapse, (B)NRM, (C) OS, (D) LFS, and (E) EFS.\u003c/p\u003e","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5222638/v1/4ce03219b815a1d0c53674d5.jpg"},{"id":68540934,"identity":"e5000e40-3d05-4cc8-b3c0-a77ce3024e6b","added_by":"auto","created_at":"2024-11-08 10:49:27","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":2024244,"visible":true,"origin":"","legend":"","description":"","filename":"Manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5222638/v1_covered_3fa45b49-0352-4b6d-80f4-af8d99e1ee6d.pdf"},{"id":67295054,"identity":"93b554fb-eaa8-4e9e-b3e3-a5e16b5ac805","added_by":"auto","created_at":"2024-10-23 10:52:27","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":1440310,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"SupplementalAppendix.docx","url":"https://assets-eu.researchsquare.com/files/rs-5222638/v1/f414b0b20ea5b584b942a76c.docx"}],"financialInterests":"There is \u003cb\u003eNO\u003c/b\u003e conflict of interest to disclose.","formattedTitle":"Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group.","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-5222638/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5222638/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"It was commonly accepted that adverse-risk acute myeloid leukemia patients should receive allogeneic hematopoietic stem cell transplantation (allo-HSCT) in first complete remission (CR1). In this multicenter study, we aimed to compare the post-transplant outcomes between patients receiving venetoclax with azacitidine (VEN-AZA, n = 47) and intensive chemotherapy (IC, n = 264) before allo-HSCT. In total cohort, the 3-year probabilities of overall survival, leukemia-free survival, and event-free survival of IC group were all better than VEN-AZA group, particularly for the patients with ASXL1 mutation or with SF3B1 mutation. Even in the patients ≥ 55 years or those with HCT-CI ≥ 1 scores before allo-HSCT, the survival of VEN-AZA group was not superior to the IC group. After propensity score matching, the overall survival at 1 year after allo-HSCT for IC group was better than that of VEN-AZA group (93.6 vs. 78.0%, P = 0.034), and the other clinical outcomes were comparable between VEN-AZA and IC groups. TP53 mutation was the most important adverse prognostic factor for post-transplant relapse and survival. Thus, our results did not support the preferential use of VEN-AZA over IC regimens in young and medical fit adverse-risk AML patients who would receive allo-HSCT in CR1.","manuscriptTitle":"Venetoclax and azacitidine compared with intensive chemotherapy for adverse-risk acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation in first complete remission: a multicenter study of TROPHY group.","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-10-23 10:44:23","doi":"10.21203/rs.3.rs-5222638/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"73d2a314-340a-4183-ab59-15f33ed3d179","owner":[],"postedDate":"October 23rd, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":39083967,"name":"Biological sciences/Cancer/Haematological cancer/Leukaemia/Acute myeloid leukaemia"},{"id":39083968,"name":"Health sciences/Diseases/Haematological diseases/Haematological cancer/Leukaemia/Acute myeloid leukaemia"},{"id":39083969,"name":"Health sciences/Diseases/Cancer/Haematological cancer/Leukaemia/Acute myeloid leukaemia"},{"id":39083970,"name":"Health sciences/Diseases/Cancer/Cancer therapy/Chemotherapy"},{"id":39083971,"name":"Biological sciences/Immunology/Bone marrow transplantation"}],"tags":[],"updatedAt":"2024-11-08T10:41:17+00:00","versionOfRecord":[],"versionCreatedAt":"2024-10-23 10:44:23","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-5222638","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5222638","identity":"rs-5222638","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}